成警花 李建 向兰 马超 蒋梅 徐静

    [摘要] 免疫检查点抑制剂已成为恶性肿瘤的重要治疗手段之一，其免疫相关性肠炎的发生率也随之增加。本例为1 位78岁的 IA2期非小细胞肺腺癌的男性患者术后复发转移，经靶向治疗联合化疗后出现严重骨髓抑制，给予信迪利单抗联合安罗替尼治疗后患者出现腹泻、腹痛、大便隐血等不适，肠镜及病理活检确诊为急性肠炎。信迪利单抗诱发免疫性肠炎尚未见病例报道，为增强临床医师对信迪利单抗相关不良反应的认识以及处理，更加科学合理地将信迪利单抗运用于恶性肿瘤的治疗中，特此报道。

    [关键词] PD-1抑制剂;免疫性肠炎;糖皮质激素;药品不良反应

    [中图分类号] R730.5; R969? [文献标识码] A? [文章编号] 2095-0616(2022)06-0193-04

    A case of sintilimab-induced immune-related enteritis

    CHENG? Jinghua1LI? JianXIANG? LanMA? ChaoJIANG? MeiXU? Jing

    1. Guizhou University of Traditional Chinese Medicine， Guizhou， Guiyang 550002， China;2. Department of Oncology， The Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine， Guizhou， Guiyang 550003， China

    [Abstract] Immune checkpoint inhibitors have become one of the important treatment methods for malignant tumors， and the incidence of immune-related enteritis has increased accordingly. This case is a 78-year-old male patient with stage IA2 non-small cell lung adenocarcinoma who developed postoperative recurrence and metastasis. After targeted treatment combined with chemotherapy ......